New perspectives in optimizing treatment of coronary heart disease and arterial hypertension patients
Abstract
Aim. To increase treatment effectiveness in patients with coronary heart disease (CHD) and arterial hypertension (AH).
Material and methods. In total, 104 patients with stable effort angina (SEA) and AH, including 52 subjects receiving combination standard antihypertensive and anti6ischemic therapy, and 52 also receiving trimetazidine, were included in the study. Cardiac patients were examined according to medical standard OST 91500.11.0002-2002. Quality of life (QoL) was assessed with a special questionnaire, «Quality of Life Index Cardiac Version IV».
Results. Increased clinical effectiveness and improved QoL was observed among SEA and AH patients receiving combination therapy including slow6release trimetazidine.
Conclusion. Adding trimetazidine MB to combination therapy of SEA and AH patients improved the quality of pathogenetic treatment.
References
1. Мартынов А.И., Остроумова О.Д., Ролик Н.Л. Артериальная гипертензия у больных пожилого и старческого возраста: этиология, клиника, диагностика, лечение. Клин мед 1997; 12: 8-13.
2. Белоусов Ю.Б., Леонова М.В., Белоусов Д.Ю. и др. Основы клинической фармакологии и рациональной терапии: руководство для практикующих врачей. Под общ. ред. Ю.Б. Белоусова, М.В. Леоновой. Москва «Бионика» 2002; 368 с.
3. Оганов Р.Г., Глезер М.Г., Деев А.Д. от имени участников. Результаты Российского исследования ПАРАЛЛЕЛЬ: ПрограммА по выявлению пациентов с неэффективной терапией β-адреноблокаторами и сРАвнитеЛьной оценке эффективности добавЛЕния к терапии триметазидина МВ или изосорбида динитрата при стабиЛЬной стенокардии. Кардиология 2007; 3: 4-13.
4. Сердечная недостаточность. ОСТ 91500.11.0002-2002. – [Электр. рес.].
5. Eastaugh JL, Calvert MJ, Freemantle N. Highlighting the need for better patient care in stable angina: results of the international Angina Treatment Patterns (ATP) Survey in 7074 patients. Family Practice 2005; 22: 43-50.
6. Hanania G, Haiat R, Olive T, et al. Coronary artery disease observed in general hospitals: ETTIC study. Comparison between trimetazidine and mononitrate isosorbide for patients receiving betablockers. Ann Cardiol Angeiol (Paris) 2002; 51(5): 268-74.
7. Michaelides AP, Spiropoulos K, Dimopoulos K, et al. Antianginal Efficacy of the combination of Trimetazidine-Propranolol Compared with Isosorbide Dinitrate-Propranolol in Patient with Stable Angina. Clin Drug Invest 1997; 13(1): 8-14.
8. The HOPE study investigator. The HOPE (Heart Outcomes Prevention Evaluation) study: the design of a large, simple randomized trial of an angiotensin6converting enzyme inhibitor (ramipril) and vitamin E in patients at high risk of cardiovascular events. J Cardiol 1996; 12: 127-37.
9. The American Association of Cardiovascular and Pulmonary Rehabilitation (AACVPR) – [Электр. рес.: http://www.aacvpr.org/resources/publications/index.cfm].
10. The Guidelines Advisory Committee (GAC) Recommended Clinical Practice Guidelines – [Электр. рес.: http://www.gacguidelines.ca].
Review
For citations:
Nikolaev N.A. New perspectives in optimizing treatment of coronary heart disease and arterial hypertension patients. Cardiovascular Therapy and Prevention. 2008;7(1):33-38. (In Russ.)
Views:
495
Email this article 
